the positive rate of egf-r increased in the precancerous lesions , whereas it decreased in invasive and metastatic cancer ( mild dysplasia : 36 % , moderate dysplasia : 57 % , severe dysplasia : 77 % , carcinoma in situ : 82 % , microinvasive carcinoma : 80 % , squamous cell carcinoma : 24 % , glandular dysplasia : 67 % , adenocarcinoma in situ : 75 % , adenocarcinoma : 8 % , adenosquamous carcinoma : 33 % , metastatic carcinoma of the pelvic lymph node : 21 % ) .
C0334048
severe dysplasia
C0334276
adenocarcinoma in situ